

**AMENDMENTS TO THE CLAIMS:**

Without prejudice or disclaimer, please amend claim 1 and add claims 8 and 9 as follows, where changes are shown relative to the issued claims of 5,760,069, according to 37 CFR § 1.173(b)(2):

1. (Amended) A method of decreasing mortality caused by congestive heart failure in a patient in need thereof which comprises administering a therapeutically acceptable amount of carvedilol in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of an angiotensin converting enzyme inhibitor (ACE), a diuretic, and digoxin,

wherein the administering comprises administering to said patient daily maintenance dosages for a maintenance period to decrease a risk of mortality caused by congestive heart failure, and said maintenance period is greater than six months.

8. (New) A method according to claim 1, wherein the daily maintenance dosages and the maintenance period have been shown to statistically decrease the risk of mortality caused by congestive heart failure.

9. (New) A method according to claim 1, wherein said patient has class II-IV congestive heart failure.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com